| Literature DB >> 35957062 |
Sarah Bouaouina1, Abdelhakim Aouf1, Abdelaziz Touati2, Hatem Ali3, Manal Elkhadragy4, Hany Yehia5,6, Amr Farouk7.
Abstract
The emergence of multidrug-resistant (MDR) bacteria is a danger to public health and exposes patients to high risk, increasing morbidity and mortality worldwide. For this purpose, three months of evaluation of MDR's prevalence and antimicrobial susceptibility patterns in the military regional university hospital of Constantine from different services and samples was carried out. Among a total of 196 isolates, 35.2% were MDR. The use of essential oils such as Origanum glandulosum Desf. as an alternative to antibiotics is attractive due to their rich content of bioactive compounds conferring many biological activities. Also, to overcome the drawbacks of using oils as the hydrophobicity and negative interaction with the environmental conditions, in addition to increasing their activity, encapsulation for the oil was performed using high-speed homogenization (HSH) into nanocapsules and high-pressure homogenization (HPH) into nanoemulsion. Nine volatile constituents were determined using gas chromatography-mass spectrometry analysis (GC-MS) in hydrodistilled oil with thymol, carvacrol, p-cymene, and γ-terpinene as dominants. A dramatic decrease in the major volatile components was observed due to the use of HSH and HPH but generated the same oil profile. The mean particle size of the nanoemulsion was 54.24 nm, while that of nanocapsules was 120.60 nm. The antibacterial activity of the oil and its nanoparticles was estimated on MDR isolates using the disk diffusion, aromatogram, and broth microdilution methods. Consistent with the differences in volatile constituents, the oil exhibited a higher antibacterial activity compared to its nanoforms with the diameters of the inhibition zone against E. coli (20 mm), S. aureus (35 mm), and A. baumannii (40 mm). Both formulations have shown relatively significant activity against the biofilm state at sub-inhibitory concentrations, where nanoemulsion was more potent than nanocapsules. The results obtained suggested that nanoformulations of essential oils are strongly recommended for therapeutic application as alternatives to antibiotics.Entities:
Keywords: Origanum glandulosum Desf; anti-biofilm activity; antibacterial activity; multidrug resistant bacteria; nanoencapsulation
Year: 2022 PMID: 35957062 PMCID: PMC9370196 DOI: 10.3390/nano12152630
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.719
Chemical constituents of O. glandulosum Desf. Oil and its nanoparticles.
| S/N | Compound | KI a | % Area b | Identification Method c,d | ||
|---|---|---|---|---|---|---|
| HD | Nanoemulsion | Nanocapsules | ||||
| 1 | α-Thujene | 928 | n.d. | n.d. | 1.08 ± 0.05 | MS, KI, & ST |
| 2 | α-Pinene | 932 | 0.21 ± 0.04 | 0.68 ± 0.02 | 1.73 ± 0.07 | MS, KI, & ST |
| 3 | Camphene | 971 | n.d. | n.d. | 0.39 ± 0.01 | MS & KI |
| 4 | 1-Octen-3-ol | 973 | n.d. | 1.29 ± 0.13 | 1.64 ± 0.03 | MS & KI |
| 5 | 3-Octanone | 981 | n.d. | 0.38 ± 0.05 | 0.58 ± 0.04 | MS & KI |
| 6 | β–Myrcene | 991 | 0.15 ± 0.03 | 0.79 ± 0.05 | 1.66 ± 0.08 | MS, KI, & ST |
| 7 | α-Terpinene | 1004 | n.d. | 0.73 ± 0.08 | 2.39 ± 0.1 | MS, KI, & ST |
| 8 | p-Cymene | 1008 | 27.56 ± 0.43 | 19.78 ± 0.16 | 18.58 ± 0.30 | MS, KI, & ST |
| 9 | Limonene | 1029 | n.d. | 0.64 ± 0.07 | 1.09 ± 0.06 | MS & KI |
| 10 | Eucalyptol | 1035 | n.d. | n.d. | 0.35 ± 0.07 | MS & KI |
| 11 | γ-Terpinene | 1088 | 5.59 ± 0.06 | 0.77 ± 0.09 | 4.52 ± 0.12 | MS, KI, & ST |
| 12 | Linalool | 1089 | n.d. | 2.98 ± 0.10 | 2.97 ± 0.25 | MS, KI, & ST |
| 13 | Borneol | 1148 | n.d. | 1.13 ± 0.09 | 2.43 ± 0.17 | MS, KI, & ST |
| 14 | Terpinen-4-ol | 1155 | n.d. | 2.73 ± 0.16 | 2.95 ± 0.09 | MS, KI, & ST |
| 15 | α-Terpineol | 1165 | n.d. | 1.53 ± 0.02 | 1.30 ± 0.12 | MS & KI |
| 16 | Thymol methyl ether | 1231 | n.d. | 0.73 ± 0.05 | 0.74 ± 0.05 | MS & KI |
| 17 | Thymol | 1267 | 49.52 ± 0.72 | 51.42 ± 0.36 | 39.47 ± 0.45 | MS, KI, & ST |
| 18 | Carvacrol | 1276 | 16.13 ± 0.35 | 9.96 ± 0.26 | 7.07 ± 0.10 | MS, KI, & ST |
| 19 | β–Caryophyllene | 1414 | 0.53 ± 0.02 | 0.78 ± 0.10 | 1.34 ± 0.12 | MS & KI |
| 20 | α-Humulene | 1451 | 0.12 ± 0.07 | n.d. | n.d. | MS & KI |
| 21 | β–Bisabolene | 1502 | 0.18 ± 0.07 | 0.89 ± 0.11 | 1.57 ± 0.11 | MS & KI |
| 22 | β-Sesquiphellandrene | 1511 | n.d. | n.d. | 0.65 ± 0.09 | MS & KI |
| 23 | Caryophyllene oxide | 1576 | n.d. | 1.37 ± 0.09 | 1.54 ± 0.14 | MS & KI |
| Total | - | 99.99 | 98.58 | 96.04 | - | |
a Confirmed by comparison with Kovat’s index on a DB5 column [21]. b Values represent averages ± standard deviations for triplicate experiments. c Confirmed by comparison with the mass spectrum of the authentic compound. d Identification by comparison with data obtained from the NIST mass spectra library. n.d.: not detected.
Average size and z-Potential of O. glandulosum Desf. oil nanoemulsion and nanoencapsulation.
| Type of Particles | Size (nm) | Zeta Potential | PDI |
|---|---|---|---|
| Nanocapsules | 120.60 ± 18.37 | −15.5 ± 0.32 | 0.244 ± 0.05 |
| Nanoemulsion | 54.24 ± 1.29 | −26.2 ± 2.6 | 0.296 ± 0.09 |
Figure 1Particle size distribution of (A) O. glandulosum Desf. oil nanocapsules and (B) nanoemulsion.
Figure 2Distribution of clinical bacterial isolates according to specimens.
Figure 3Distribution of isolates according to hospital departments.
Antimicrobial susceptibility patterns of MDR Gram-negative pathogens isolates against commonly used antimicrobials agents.
| ATBs | Percentage of Resistance (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AMP | 100% | 100% | 100% | 100% | 100% | NT | 100% | 100% | 100% | NT |
| AMX | 100% | 100% | 100% | 100% | 100% | NT | 100% | 100% | 100% | NT |
| AMC | 100% | 100% | 100% | 100% | 100% | NT | 100% | 88% | 91% | NT |
| TIC | 100% | 0% | 100% | 100% | 100% | 100% | 50% | 94% | 95% | 100% |
| PRL | 100% | 0% | 100% | 100% | 100% | 100% | 50% | 100% | 95% | 100% |
| CF | 100% | 75% | 100% | 100% | 100% | NT | 100% | 100% | 100% | NT |
| CTX | 100% | 100% | 100% | 100% | 100% | NT | 50% | 88% | 86% | NT |
| CRO | 100% | 25% | 100% | 100% | 100% | NT | 50% | 88% | 86% | NT |
| IMP | 0% | 0% | 0% | 100% | 0% | 50% | 0% | 5% | 8% | 66% |
| AK | 100% | 0% | 0% | 0% | 0% | 0% | 0% | 11% | 0% | 0% |
| GN | 100% | 0% | 0% | 100% | 100% | 50% | 0% | 61% | 34% | 100% |
| TCC | NT | NT | NT | NT | NT | 100% | NT | NT | NT | NT |
| NA | 0% | 0% | 100% | 100% | 50% | NT | 100% | 61% | 56% | NT |
| OFX | 100% | 0% | 0% | 100% | 50% | NT | 100% | 50% | 43% | NT |
| CIP | 100% | 0% | 0% | 100% | 50% | NT | 50% | 55% | 39% | NT |
| TZP | NT | NT | NT | NT | NT | 100% | NT | NT | NT | 33% |
| CT | 100% | 0% | 0% | 100% | 100% | 0% | 100% | 5% | 0% | 33% |
| SXT | 100% | 75% | 100% | 50% | 100% | 50% | 100% | 77% | 91% | 100% |
| ATM | NT | NT | NT | NT | NT | 50% | NT | NT | NT | 33% |
| CAZ | NT | NT | NT | NT | NT | 100% | NT | NT | NT | 100% |
| LEV | NT | NT | NT | NT | NT | 0% | NT | NT | NT | 66% |
| RD | NT | NT | NT | NT | NT | 0% | NT | NT | NT | 33% |
| NET | NT | NT | NT | NT | NT | 0% | NT | NT | NT | 66.66% |
ATBs: Antibiotics, NT: not tested, AMP: Ampicillin, AMX: Amoxicillin, AMC: Amoxicillin/clavulanate TIC: Ticarcillin, PRL: Piperacillin, CF: Cefazolin, CTX: Cefotaxime, CRO: Ceftriaxone, IMP: Imipenem, GN: Gentamicin, OFX: Ofloxacin, CIP: Ciprofloxacin, CT: Colistin, SXT: Trimethoprim/Sulfamethoxazole, AK: Amikacin, TCC: Ticarcillin-clavulanate, TZP: Piperacillin-clavulanate, CAZ: Ceftazidime, ATM: Aztreonam, LEV: Levofloxacin, NET: Netlmicin, RD: Rifampicin, NA: Nalidixic acid.
Antimicrobial susceptibility patterns of Methicillin-resistant S. aureus against antimicrobial agents.
| Antibiotics (ATBs) | Resistance Percentage (%) |
|---|---|
| P | 100% |
| OX | 100% |
| FOX | 100% |
| E | 21% |
| SP | 14% |
| L | 14% |
| DA | 14% |
| PT | 7% |
| VA | 0% |
| AK | 28% |
| GN | 42% |
| OFX | 21% |
| FD | 42% |
| TEC | 0% |
| TE | 42% |
| DO | 14% |
| C | 0% |
| RD | 7% |
P: Penicillin, OX: Oxacillin, FOX: Cefoxitin, SP: Spriramycin, DA: Clindamycin, PT: Pristinamycin, L: Lincomycin, E: Erythromycin, RD: Rifampicin, VA: Vancomycin, AK: Amikacin, OFX: Ofloxacin, TEC: Teicoplanin, TE: Tetracycline, DO: Doxycycline, FD: Fusidicacid, C: Champenicol, GN: Gentamicin.
Antibacterial activity of O. glandulosum HD oil and its nanoparticles against multidrug resistant isolates using three methods (Aromatogram, MIC, and MBC).
| Strains |
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|
| IZ * | MIC | MBC | IZ | MIC | MBC | IZ | MIC | MBC | |
|
| 13 | 0.62% | 0.62% | NA ** | / | / | 11 | 31.25 | 31.25 |
|
| 15 | 0.62% | 1.25% | NA | / | / | NA | / | / |
|
| 40 | 0.07% | 0.15% | 16 | 62.5 | 125 | 11 | 31.25 | 31.25 |
|
| 16 | 0.31% | 0.31% | NA | / | / | 11 | 31.25 | 125 |
|
| 35 | 0.15% | 0.15% | 12 | 62.5 | 62.5 | 13 | 31.25 | 62.5 |
|
| NA | / | / | NA | / | / | NA | / | / |
|
| 20 | 0.15% | 0.15% | 12 | 62.5 | 125 | 20 | 31.25 | 250 |
|
| 17 | 0.15% | 0.15% | 15 | 31.25 | 125 | 20 | 31.25 | 250 |
|
| 22 | 0.15% | 0.15% | 20 | 31.25 | 62.5 | 20 | 31.25 | 125 |
* IZ: inhibition zone, ** NA: not active.
Figure 4The inhibitory effect of O. glandulosum essential oil and their nanoformulations on biofilm formation by pathogenic bacteria: (A) effect of nanoemulsion, (B) effect of nanocapsules, and (C) effect of HD oil.